NCT05217667Phase 2Terminated

Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Study sponsor: Arrowhead Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2023-05-02Actual
Enrollment · participants18Actual
Source updated2026-06-12Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Percent Change from Baseline in Fasting Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) and LDL-C by Preparative Ultracentrifugation (LDL-C [PUC]) up to Week 24

+ After

Measure: Percent Change From Baseline in Fasting LDL-C at Week 24

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source